Total Funding
40
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
165670
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Asi Haviv: VP of Clinical DevelopmentPast Role: Teva Pharmaceuticals, Director
Shoshie Katz: VP RA/QAPast Role: BioReliance, QA and RA Positions
About the Company
Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It
is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.
